Clinical trials: Solid Tumor, completed
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Tumors
An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
- Trial name
- NCT02182206
- Testing
- BIBF 1120
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with leucovorin and fluorouracil in treating young patients with advanced solid tumors.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00281944
- Testing
- oxaliplatin, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Lymphoma
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with…
- Conditions
- Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT05093322
- Testing
- Surufatinib in combination with Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hutchmed
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Evaluation of a Couple-Based Physical Activity Intervention
This clinical trial tests how well a couple-based physical activity (PA) intervention, Mates in Motion, works in patients undergoing hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell therapy (CART) and…
- Trial name
- NCT06073951
- Testing
- Best Practice, Exercise Counseling, Exercise Intervention
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Advanced Solid Tumors
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
- Trial name
- NCT00739453
- Testing
- OSI-906, erlotinib
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Thrombocytopenia
A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with chemotherapy-induced thrombocytopenia (CID).
- Trial name
- NCT06521931
- Testing
- PN20
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Neoplasm Malignant
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Primary Objective: Part A - Monotherapy: To determine the maximum tolerated dose (MTD) of SAR260301 administered as monotherapy and either on a once or twice daily schedule, to patients with advanced solid tumors or lymphomas.
- Trial name
- NCT01673737
- Testing
- SAR260301, Vemurafenib
- Where
- 4 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Sanofi
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Lung Cancer, Small Cell, Solid Tumor Cancer
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
The purpose of this study is to compare two capsules of topotecan made by slightly different methods. This will be done by giving the drug made by the two different methods to patients orally and testing blood levels.
- Trial name
- NCT00046111
- Testing
- topotecan
- Where
- 5 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Adult
A Study of CS1002 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
- Trial name
- NCT03523819
- Testing
- CS1002, CS1003
- Where
- 10 sites in Australia, Hong Kong
- Volunteers
- 91 people
- Sponsor
- CStone Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00423865
- Testing
- cisplatin, everolimus, gene expression analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced and Metastatic Solid Tumor
Regorafenib and Nivolumab Simultaneous Combination Therapy
the efficacy and safety ofhe use of regorafenib in combination with nivolumab
- Trial name
- REGONIVO (NCT03406871)
- Testing
- Regorafenib, Nivolumab
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Kohei Shitara
Advanced Solid Tumor
CLN-418 Study on Subjects With Advanced Solid Tumors
Study to evaluate the safety and tolerability of the study drug CLN-418, to determine the maximum tolerated dose and/or recommended Phase 2 study dose of CLN-418.
- Trial name
- NCT05306444
- Testing
- CLN-418
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Harbour BioMed US, Inc.
Solid Tumor
A Study of of MORAb-004 in Subjects With Solid Tumors
The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.
- Trial name
- NCT00847054
- Testing
- MORAb-004 (monoclonal antibody to TEM1)
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Morphotek
Cancer
Continuation Study of the Oral AKT Inhibitor GSK2110183
This multicenter, non-randomized, open-label, treatment continuation or 'rollover' study was designed to provide continued access to eligible subjects who had previously participated in a GSK2110183 study (parent study) sponsored…
- Trial name
- NCT01531894
- Testing
- GSK2110183 (afuresertib)
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Phase 1a/1b Trial to evaluate the tolerability and safety of IBI101 monotherapy or in combination with Sintilimab in advanced solid tumor patients.
- Trial name
- NCT03758001
- Testing
- IBI101, Sintilimab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.
- Trial name
- NCT04346381
- Testing
- Camrelizumab, Famitinib
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid…
- Trial name
- NCT00878800
- Testing
- PXD101, Doxorubicin
- Where
- 3 sites in Denmark, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Valerio Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.